Tango Therapeutics President R&D Crystal Adam sells USD 572,610 common shares

Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

0.00
  • Tango Therapeutics President, R&D Crystal Adam sold 27,000 common shares on May 1, 2026 at average prices of USD 21.19 and USD 22.
  • Sale followed exercise of 27,000 stock options at USD 5.2 per share on same day.
  • Adam ended day with 115,743 common shares beneficially owned.
  • Adam also reported 368,040 stock options beneficially owned following transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-207096), on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.